Table 1.
Summary of the impact of different IL28B polymorphisms on HCV infection in several conditions (SVR: sustained virological response; RVR: rapid virological response).
| Polymorphism | Genotype | Impact on HCV | Impact on HCV/HIV | Impact on liver graft reinfection |
|---|---|---|---|---|
| rs12979860 | C/C | (i) Higher SVR (genotypes 1, 2, 3, 4) [11, 41–45] (ii) Spontaneous clearance [11] (iii) Early viral kinetics [46, 47] |
(i) Higher SVR [51] (ii) No influence on acute HCV infection [50] (iii) Higher all-cause mortality [52, 53] |
(i) Natural course and treatment outcome dependent on donor rather than recipient genetic background [54] (ii) Higher frequency of posttransplant diabetes mellitus [55] |
|
| ||||
| rs8099917 | T/G or T/T | (i) Treatment failure (genotypes 1, 2, 4) [12, 56] (ii) Increased viral clearance and virological response in Taiwanese patients [57] |
(i) SVR in patients with recurrent HCV infection [58] | |
| G/G | (i) High prevalence [59] (ii) Treatment failure (genotype 1) [60] |
|||
|
| ||||
| Combined | C/C and T/T | (i) Spontaneous clearance [61] (ii) Early viral kinetics [62, 64, 65] (iii) RVR but not SVR (genotype 3) [63] |
(i) Early viral kinetics (genotypes 1, 4) [65] | |